Foundayo Misses Wegovy Pill’s Early Performance, But Lilly Isn’t Worried
While Foundayo’s early launch metrics appear to fall short of those for the Wegovy pill, Lilly is talking a slow, steady ramp and an eye to building the oral GLP-1 internationally.
Scrip - April 30, 2026

BMS Looks Ahead To Catalyst-Rich 2026
The drugmaker reported steady growth for Eliquis in the first quarter while anticipating several oncology and cardiovascular readouts over the course of the year.
Scrip - April 30, 2026

Merck’s Enlicitide Launch Timing Depends On CNPV Discussions
The oral PCSK9 inhibitor could be a big growth driver for Merck & Co., with a launch targeted for the second half of the year.
Scrip - April 30, 2026

Hundreds Of Injuries From Tubing Tear Prompts Insulet Pump Recall
Insulet is recalling certain Omnipod 5 Pods after discovering an internal tubing tear that could disrupt insulin delivery. The FDA has labeled the recall Class I, its most serious type.
Medtech Insight - April 30, 2026

GE HealthCare Cuts Profit Outlook On Inflation, Memory Chip Costs As Flyrcado Run Rate Doubles
GE HealthCare's pipeline had a strong quarter. Flyrcado's run rate nearly doubled. A manganese-based MRI agent cleared Phase 1. China stabilized. Then a $250m inflation bill – led by memory chip costs – forced the company to cut its adjusted EPS guidance for 2026.
Medtech Insight - April 30, 2026

Baxter Q1 results beat low expectations amid turnaround push
Beleaguered company posted stronger-than-expected international sales in Q1 as CEO Andrew Hider pushes for restructuring and a sharper R&D focus.
Medtech Insight - April 30, 2026

PureTech Wants To Get Its Hub-And-Spoke Model Spinning Faster
The Boston-based company’s CEO hopes to generate more spin-out companies more quickly and bring in outside investors sooner.
Scrip - April 30, 2026

Italian Women More Impacted By Minor Ailments But Better At Self-Care
Italian women experience minor ailments at higher rates than men but demonstrate superior self-care practices, with nearly all reading package leaflets, checking expiry dates and preferring pharmacists over AI, according to a new Assosalute-Censis report.
HBW Insight - April 30, 2026

GLP-1 Focus Central To Haleon’s North America Turnaround
Serving the growing number of consumers using prescription GLP-1 receptor agonist drugs for obesity and type 2 diabetes represents a key piece of Haleon's growth strategy for North America.
HBW Insight - April 30, 2026

Leo Leaps Into Gene Therapy With Replay Acquisition
The Denmark-based medical dermatology specialist has paid $50m upfront to bag a preclinical herpes simplex virus gene therapy for the treatment of dystrophic epidermolysis bullosa.
Scrip - April 30, 2026

Executives On The Move: Kai Beckmann Takes The Helm At Merck KGaA
Recent changes in the industry include C-suite changes at Inventiva and internal moves at Amgen, plus Ardelyx gets a new chief legal officer from Bristol Myers Squibb.
Scrip - April 30, 2026

Teva Locks In Tourette’s Frontrunner With $700m Emalex Buy
Teva bets $700m upfront on a late-stage Tourette's drug that could potentially fill a treatment gap affecting half the patients with the condition.
Scrip - April 30, 2026

TytoCare De Novo Could Transform ENT Diagnosis, Accelerating At-Home Care
New York-based TytoCare has secured de novo authorization for its ENT software suite, which works in conjunction with the company’s compatible digital otoscope to provide AI-powered eardrum analysis at home. The de novo classification creates a new regulatory ENT category.
Medtech Insight - April 30, 2026

Xbrane Resubmits Ranibizumab In The US – Can It Succeed This Time?
Marking the latest attempt to compete in the US biosimilar Lucentis market, Sweden’s Xbrane Biopharma has once again submitted a BLA for ranibizumab to the US FDA.
Generics Bulletin - April 30, 2026

French HTA Body Slams Pharma Companies For Increasing ‘Unacceptable’ Behavior
The French health technology assessment body, HAS, says a trend had developed recently of pharmaceutical companies trying to undermine its scientific opinions and its independence.
Medtech Insight - April 30, 2026

Independent Samsung Bioepis Reports Continued Quarterly Growth
Strong financials, a growing direct sales footprint, and fresh pipeline deals signal Samsung Bioepis is building for more than just another solid quarter.
Generics Bulletin - April 30, 2026

Mum’s The Word On Teva’s Tyvaso Strategy
Teva has declined to clarify plans around generic Tyvaso despite a 2018 settlement allowing market entry, as strong Phase III data in IPF boosts the drug’s potential and raises questions over a delayed entry into a potentially multi-billion-dollar market.
Generics Bulletin - April 30, 2026

Astellas Braces For Xtandi LoE By Broadening Strategic Products
Astellas logs record annual revenue on the back of mainstay growth, while planning to expand Padcev’s indications in multiple markets and moving other key candidates into Phase III.
Scrip - April 30, 2026